PSA Testing in the UK: What Is Changing and What Current NHS Guidance Says

Reports that middle-aged men could lose the right to a prostate-specific antigen (PSA) test without symptoms have generated significant debate in the UK. The LBC article at the centre of the discussion describes controversial new plans around NHS GP guidance for PSA testing, with the headline suggesting middle-aged men would lose access to testing without symptoms.

It is important to be clear from the outset: as of the latest verified position in 2026, this appears to be a reported proposal and draft recommendation rather than a confirmed, implemented change to NHS policy for all men. The current NHS position remains that PSA testing is not offered as a routine population screening programme, but men without symptoms can still discuss testing with their GP under the Prostate Cancer Risk Management Programme.

This article explains what is reportedly changing, what the NHS currently says, why PSA testing is complex, and what it means for men in the UK.

What Is Changing Around PSA Testing?

The reporting in LBC refers to proposed changes that would affect whether asymptomatic men can routinely access PSA testing through their GP. To understand the proposal, two separate concepts need to be distinguished.

1. Current guidance for asymptomatic men: Under the NHS Prostate Cancer Risk Management Programme (PCRMP), the wording has been consistent: “Any asymptomatic man, aged 50 and over can make an appointment with their GP to discuss having the PSA test. GPs should not proactively raise the issue with asymptomatic men.” This allows an informed choice after balanced information.

2. Proposed or draft changes: Recent discussion has focused on whether this approach should change, particularly in the context of overtesting, inconsistent retesting intervals, pressure on diagnostic services, and the growth of PSA testing in community settings. Some expert consensus statements have suggested moving away from a blanket reactive approach and towards more proactive discussions only with men at higher-than-average risk, such as Black men, those with a family history of prostate cancer, or those with genetic risk factors like BRCA2.

The UK National Screening Committee (UK NSC) context is also critical. In November 2025, the UK NSC opened a draft recommendation and public consultation that supported a risk-stratified approach rather than population-wide prostate-specific antigen (PSA) screening. As of May 2026, the committee does not recommend population screening for prostate cancer. It does recommend PSA testing every two years for men aged 45 to 61 years who have a pathogenic BRCA2 variant with a family history of certain cancers. The committee says that the best approach to identifying and inviting groups at high genetic risk should be evaluated over time.

In response to that, ministers in England have agreed to implement a nationally managed approach to biennial (once every 2 years) PSA testing in men aged 45 to 61 who have pathogenic germline BRCA2 variants with a family history of breast, ovarian, pancreatic or prostate cancer. For the rest of the population, the committee continues to advise against population screening where there is an absence of evidence or evidence that screening would do more harm than good.

The LBC report should therefore be read as describing proposed or draft guidance that has not yet been confirmed as final NHS policy for all men.

What Does the NHS Currently Say About PSA Tests?

The NHS does not currently have a national screening programme for prostate cancer in the same way it does for bowel, breast and cervical cancer. This is a key distinction that is often confused in media coverage.

Current NHS guidance advises:

• Men with symptoms: NICE guideline NG12 recommends that GPs consider a PSA test and digital rectal examination (after counselling) where symptoms raise suspicion of prostate cancer.
• Men without symptoms: Under the PCRMP, GPs should not proactively raise PSA testing, but should provide balanced information if an asymptomatic man aged 50 or over asks about it and wishes to discuss it. This allows an informed choice to be made.
• Men at higher risk: Men aged 45 or over who are at higher-than-average risk due to Black ethnicity, family history, or confirmed genetic risk factors such as BRCA2 may wish to discuss testing earlier. Current expert consensus published in 2025-2026 is moving towards GPs proactively discussing prostate cancer risk with these groups, which would be a shift from previous PCRMP wording that advised against proactive raising.
• Retesting: Current NHS guidance provides no clear recommendation on how often asymptomatic men should be retested or at what age testing should stop, which has contributed to variation in practice and concerns about overtesting in wealthier areas.

There are currently no clinically validated and reliable at-home PSA tests that are suitable for use in the NHS by asymptomatic men in any risk category, according to parliamentary written answers reviewing the evidence.

What Is a PSA Test?

PSA stands for prostate-specific antigen. It is a protein made by both normal and abnormal cells in the prostate gland.

A PSA test is a blood test that measures the level of PSA in the blood. In simple terms, it is not a cancer test in itself, but a marker that can indicate that something is happening in the prostate that may need further attention.

What can a PSA test tell you?

A raised PSA level can indicate a problem with the prostate, which could include prostate cancer, but also includes many other non-cancerous causes such as an enlarged prostate, infection or inflammation of the prostate (prostatitis), urinary tract infection, recent vigorous exercise, recent ejaculation, or recent urinary procedures.

A normal PSA result does not completely rule out prostate cancer. Some men with prostate cancer have PSA levels within the normal range, while some men with raised PSA do not have cancer. This is why PSA testing is described as complex and why informed discussion is important.

Why Can Prostate Cancer Be Difficult to Detect?

Prostate cancer often develops without obvious symptoms in its early stages, particularly when it is confined to the prostate. This is why detection can be difficult and why discussions about testing have become so important.

Where symptoms do occur, they often relate to changes in urination, such as difficulty starting to urinate, weak flow, or needing to urinate more often. However, these same symptoms are very commonly caused by non-cancerous conditions such as benign prostate enlargement, which is common in older men.

Having urinary symptoms does not automatically mean a person has prostate cancer, and not having symptoms does not guarantee the prostate is healthy. This overlap is one reason why GPs need to consider the full clinical picture rather than relying on PSA alone.

Who May Be at Higher Risk of Prostate Cancer?

Authoritative sources such as the NHS, Cancer Research UK and the UK NSC recognise several factors that can increase the risk of prostate cancer:

• Age: Risk increases with age. Prostate cancer is most common in men over 50, and the risk continues to rise with age.
• Family history: Having a father or brother who had prostate cancer increases risk, particularly if they were diagnosed at a younger age.
• Genetic factors: Certain inherited gene variants, such as pathogenic BRCA1 and particularly BRCA2 variants, are associated with higher risk. The UK NSC’s recent recommendation for targeted screening focuses specifically on BRCA2 carriers with family history.
• Ethnicity: Men with Black African or Black Caribbean backgrounds have a higher risk compared with other ethnic groups. This is recognised in recent consensus statements that recommend proactive risk discussions from age 45.

Risk is not deterministic. Having a risk factor does not mean prostate cancer will develop, and not having a risk factor does not mean it cannot develop. Individual risk should be discussed with a GP.

Why Is There Debate Over PSA Testing?

The debate reflects a genuine clinical dilemma: a test that can help detect cancer earlier, but that is not accurate enough to be used as a population screening tool without causing significant harm.

Potential benefits

An elevated PSA can lead to further assessment, potentially including MRI and biopsy, that may detect prostate cancer earlier, potentially allowing earlier treatment where appropriate. For some men, particularly those at higher risk due to BRCA2 or family history, this possibility of earlier detection is important. Early detection may mean more treatment options.

Potential harms

PSA testing also carries well-documented potential harms:

• False reassurance from a normal result when cancer is still present, leading to delayed presentation.
• False-positive or elevated results from non-cancer causes, leading to anxiety and unnecessary appointments.
• Additional tests such as repeat blood tests, MRI scans or prostate biopsies, which carry their own risks including infection and bleeding.
• Unnecessary investigations for slow-growing tumours that may never have caused symptoms or shortened life.
• Overdiagnosis, where cancer is diagnosed that would never have caused harm in a man’s lifetime.
• Overtreatment, where treatment for overdiagnosed cancer brings side effects such as urinary and erectile difficulties without extending life.

The UK NSC has concluded that the PSA test is not nearly reliable enough as a primary screening test for a national population programme because it is likely to cause more harm than good when used in that way. Cancer Research UK supports the UK NSC recommendation not to introduce a national screening programme based on PSA alone, noting evidence that giving asymptomatic men the PSA test has no mortality benefit at population level.

What Are Experts and Cancer Charities Saying?

Cancer charities and expert groups have responded cautiously to any suggestion that asymptomatic men would lose the ability to discuss PSA testing.

Prostate Cancer UK has previously emphasised the need for balanced information on the PSA blood test, explaining both benefits and limitations, so men can make an informed choice. It has also supported research into more accurate testing, including the TRANSFORM trial – the Trial of Randomised Approaches for National Screening for Men – which is exploring whether combining PSA with other tests such as rapid MRI scans could lead to a more accurate screening approach.

Clinical consensus reports published in the British Journal of General Practice in 2025 have argued that current guidelines (PCRMP and NHS) recommending GPs do not proactively raise PSA testing should evolve, with primary care professionals proactively discussing prostate cancer risk, PSA testing and the wider diagnostic pathway with men aged 45 and over at higher-than-average risk.

The UK NSC has stated it supports the recommendation not to introduce a national screening programme based on PSA alone, while supporting a targeted programme for BRCA2 carriers and collaboration with TRANSFORM.

All statements should be understood as opinions and recommendations within an evolving evidence base, not as established NHS policy until formally adopted through official channels.

What Does This Mean for Men in the UK?

For now, the established position remains:

• There is no national population screening programme for prostate cancer in the UK.
• Asymptomatic men aged 50 and over can currently ask their GP to discuss PSA testing and make an informed decision after receiving balanced information.
• A new targeted screening approach for men aged 45 to 61 with pathogenic BRCA2 variants and relevant family history has been recommended by UK NSC and accepted by government for implementation on a biennial basis.
• Any wider change to remove the right to discuss PSA testing for asymptomatic men would represent a significant policy shift and would need to be confirmed through official NHS and Department of Health and Social Care (DHSC) publications, not just a leaked letter or proposal.
• Men at higher risk due to Black ethnicity, family history or BRCA2 may be offered more proactive discussions under evolving consensus, rather than less.

Men who are concerned about prostate cancer risk, family history, or genetic factors should continue to discuss their individual circumstances with their GP rather than relying on media headlines alone.

Symptoms That Should Not Be Ignored

According to current NHS information, symptoms that can be associated with prostate problems, including prostate cancer, include:

• difficulty starting to urinate
• weak flow of urine
• needing to urinate more often than usual
• needing to urinate more urgently than usual
• waking during the night to urinate frequently
• blood in urine or semen
• erectile difficulties
• unexplained weight loss
• persistent pain in the back, hips or pelvis

These symptoms can have many causes other than prostate cancer, including benign prostate enlargement, urinary tract infections or other conditions. Anyone experiencing them should seek medical advice promptly rather than self-diagnosing or waiting.

What Happens If a PSA Result Is Raised?

A raised PSA result does not automatically mean cancer is present. It means further consideration is needed.

Depending on the clinical situation, a GP may discuss:

• repeating the PSA test after one to three months, especially if the level is borderline
• considering other factors that could explain the rise, such as recent infection or procedures
• physical examination where appropriate
• referral for further assessment in line with NICE NG12, which may include an MRI scan or, in some cases, a prostate biopsy
• referral to urology via the two-week wait pathway if prostate cancer is suspected

The exact pathway depends on individual risk, symptoms, age, PSA level and trend, and other health factors. Decisions about further tests should be made together with a healthcare professional and not based on a single PSA figure alone.

Key Takeaways

• Reports about middle-aged men losing access to PSA testing without symptoms refer to proposed or draft guidance reported by LBC, not confirmed final NHS policy for all men as of May 2026.
• Current NHS guidance under the Prostate Cancer Risk Management Programme states that any asymptomatic man aged 50 and over can make an appointment to discuss PSA testing with their GP, although GPs should not proactively raise it.
• The UK National Screening Committee does not recommend population-wide PSA screening because the test is not reliable enough and is likely to cause more harm than good, but does recommend targeted biennial PSA testing for men aged 45 to 61 with pathogenic BRCA2 variants and relevant family history.
• PSA is a blood test measuring prostate-specific antigen; it can indicate prostate problems but cannot alone diagnose prostate cancer; raised levels can have many non-cancer causes.
• Prostate cancer often has no early symptoms; urinary symptoms can have other causes such as benign enlargement.
• Recognised risk factors include age over 50, family history, BRCA1/BRCA2 variants, and Black African or Black Caribbean background.
• The debate balances potential earlier detection against potential harms including false positives, overdiagnosis and overtreatment.
• Research such as the TRANSFORM trial is exploring whether combining PSA with MRI could improve accuracy.

Conclusion

The discussion around PSA testing in the UK reflects a genuine tension between wanting to detect prostate cancer earlier and avoiding harms from an imperfect test used at population scale. The LBC report highlights a potentially significant shift in how asymptomatic men access PSA testing, but the latest verified position is that broad population screening is not recommended, while targeted screening for high genetic risk and the existing right for men aged 50 and over to discuss PSA testing with their GP remains the current framework.

For men in the UK, the most appropriate approach remains staying informed through official NHS, UK National Screening Committee and Department of Health and Social Care sources, and discussing personal risk, family history and any symptoms with a GP.

Samuel Kemp

Dr. Samuel Kemp is a Consultant Physician at the Royal Brompton Hospital with specialist expertise in respiratory medicine, including lung cancer, COPD, and advanced interventional bronchoscopy.